Skip to main content

Advertisement

Log in

Radioiodine treatment of well-differentiated thyroid cancer

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. S.M. Seidin, L.D. Marinelli, E. Oshry, Radioactive iodine therapy effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132, 838–847 (1946)

    Article  Google Scholar 

  2. W.H. Beierwaltes, R. Rabbani, C. Dmuchowski et al., An analysis of ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J. Nucl. Med. 25, 1287–1293 (1984)

    PubMed  CAS  Google Scholar 

  3. M. Schlumberger, C. Challeton, F. De Vathaire et al., Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37, 598–605 (1996)

    PubMed  CAS  Google Scholar 

  4. T. Petrich, A. Widjaja, T.J. Musholt et al., Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur. J. Nucl. Med. 28, 203–208 (2001)

    Article  PubMed  CAS  Google Scholar 

  5. A.P. Brown, W.P. Greening, V.R. McCready, H.J. Shaw, C.L. Harmer, Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br. J. Radiol. 57, 323–327 (1984)

    Article  PubMed  CAS  Google Scholar 

  6. C. Menzel, F. Grunwald, A. Schomburg et al., “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J. Nucl. Med. 37, 1496–1503 (1996)

    PubMed  CAS  Google Scholar 

  7. E. Hindié, D. Melliere, F. Lange et al., Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur. J. Nucl. Med. 30, 974–981 (2003)

    Article  Google Scholar 

  8. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)

    Article  PubMed  Google Scholar 

  9. F. Pacini, M. Schlumberger, H. Drale et al., European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006)

    Article  PubMed  CAS  Google Scholar 

  10. F. Atkins, D. Van Nostrand, Radioiodine Whole Body Imaging, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, ed. by L. Wartofsky, Van Nostrand (Humana Press, Totowa, 2006), pp. 133–150

    Google Scholar 

  11. R. McDougal, in Differentiated Thyroid Cancer, ed. by R. McDougal. Management of Thyroid Cancer and Related Nodular Disease (Springer, New York, 2006), p. 173

  12. D. Van Nostrand, M. Aiken, F. Atkins, S. Moreau, C. Garcia, E. Acio, K. Burman, L. Wartofsky, The utility of radioiodine scans prior to iodine-131 ablation in patients with well differentiated thyroid cancer. Thyroid 19, 849–855 (2009)

    Article  PubMed  Google Scholar 

  13. M.-K. Chen, M. Yasrebi, J. Samii, L.H. Staib, I. Doddamane, D.W. Cheng, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid 22, 304–308 (2012)

    Article  PubMed  CAS  Google Scholar 

  14. M.J. Schlumberger, F. Pacini, The low utility of pre-therapy scans in thyroid cancer patients. Thyroid 19, 815–816 (2009)

    Article  PubMed  Google Scholar 

  15. D. Van Nostrand, F. Atkins, F. Yeganeh et al., Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12, 121–134 (2002)

    Article  PubMed  Google Scholar 

  16. H.R. Maxon, S.R. Thomas, V.S. Hertzbert, J.G. Kereiakes, I.W. Chen, M.I. Sperling, E.L. Saenger, Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med. 309, 937–941 (1983)

    Article  PubMed  CAS  Google Scholar 

  17. S.R. Thomas, H.R. Maxon, J.G. Kereiakes, In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys. 3, 253–255 (1976)

    Article  CAS  Google Scholar 

  18. R.S. Benua, N.R. Cicale, M. Sonenberg, R.W. Rawson, The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87, 171–182 (1962)

    CAS  Google Scholar 

  19. G. Sgouros, Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med. 34, 689–694 (1993)

    PubMed  CAS  Google Scholar 

  20. R. Dorn, J. Kopp, H. Vogt et al., Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-based approach. J. Nucl. Med. 44, 451–456 (2003)

    PubMed  CAS  Google Scholar 

  21. R. Leeper, Controversies in the treatment of thyroid cancer: the New York Memorial Hospital approach. Thyroid Today 5, 1–4 (1982)

    Google Scholar 

  22. K. Kulkarni, D. Van Nostrand, F.B. Atkins, M.J. Aiken, K. Burman, L. Wartofsky, The frequency with which empiric amounts of radioiodine “over-” or “under-” treat patients with metastatic well-differentiated thyroid cancer. Thyroid 16, 1019–1023 (2006)

    Article  PubMed  CAS  Google Scholar 

  23. R.M. Tuttle, R. Leboeuf, R.J. Robbins et al., Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med. 47, 1587–1591 (2006)

    PubMed  Google Scholar 

  24. J. Klubo-Gwiezdzinska, D. Van Nostrand, F. Atkins, K. Burman, J. Jonklaas, M. Mete, L. Wartofsky, Efficacy of dosimetric versus empiric prescribed activity of 131-I for therapy of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 3217–3225 (2011)

    Article  PubMed  CAS  Google Scholar 

  25. D. Van Nostrand, Radioiodine Ablation, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edn., ed. by L. Wartofsky, D. Van Nostrand (Humana Press, Totowa, 2011), pp. 611–612

    Google Scholar 

  26. D. Van Nostrand, Radioiodine Treatment for Distant Metastases, in Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edn., ed. by L. Wartofsky, D. Van Nostrand (Humana Press, Totowa, 2006), pp. 611–612

    Google Scholar 

  27. M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet et al., Strategies of radioiodine ablation in patients with low risk thyroid cancer. N. Engl. J. Med. 366, 1663–1673 (2012)

    Article  PubMed  CAS  Google Scholar 

  28. U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke, L. Moss, A. Nicol et al., Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012)

    Article  PubMed  CAS  Google Scholar 

  29. C. Schvartz, F. Bonnetain, S. Dabakuyo, M. Gauthier, A. Cueff, S. Fieffe et al., Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J. Clin. Endocrinol. Metab. 97, 1526–1535 (2012)

    Article  PubMed  CAS  Google Scholar 

  30. R.K. Alexander, P.R. Larsen, Radioiodine for thyroid cancer—is less more? New Engl. J. Med. 366, 1732–1733 (2012)

    Article  PubMed  CAS  Google Scholar 

  31. L. Wartofsky, Management of papillary microcarcinoma: primum non nocere. J. Clin. Endocrinol. Metab. 97, 1169–1172 (2012)

    Article  PubMed  CAS  Google Scholar 

  32. EANM, EANM procedure guidelines for therapy with iodine-131. Eur. J. Nucl. Med. 30, BP27–BP31 (2003)

    Google Scholar 

  33. J.C. Reynolds, in Comparison of I-131Absorbed Radiation Doses in Children and Adults; A Tool for Estimating Therapeutic I-131 Doses in Children. ed. by J. Robbins. Treatment of Thyroid Cancer in Children, (DOE/EH-0406, US Department of Commerce Technology Administration, National Technical Information Service, Springfield, 1994), pp. 127–135

  34. M.D. Ringel, S.J. Burgun, in Recombinant Human Thyrotropin. ed. by L Wartofsky, D. Van Nostrand. Thyroid Cancer: A Comprehensive Guide to Clinical Management (Humana Press, Totowa, 2006), pp. 103–116

  35. P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri et al., Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 337, 888–896 (1997)

    Article  PubMed  CAS  Google Scholar 

  36. R.J. Robbins, R.M. Tuttle, M. Sonenberg, A. Shaha, R. Sharaf, H. Robbins, M. Fleisher, S.M. Larson, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11(9), 865–869 (2001)

    Article  PubMed  CAS  Google Scholar 

  37. R. Elisei, M. Schlumberger, A. Driedger, C. Reiners, R.T. Kloos, S.I. Sherman et al., Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 294, 4171–4179 (2009)

    Article  Google Scholar 

  38. P.W. Rosario, A.F.M. Filho, R.X. Lacerda, M.R. Calsolari, Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid 222, 332–333 (2012)

    Article  Google Scholar 

  39. C. Durante, S. Filetti, Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. J. Clin. Endocrinol. Metab. 96, 3059–3061 (2011)

    Article  PubMed  CAS  Google Scholar 

  40. R.J. Robbins, S.M. Larson, N. Sinha, A. Shaha, C. Divgi, K.S. Pentlow, R. Ghossein, R.M. Tuttle, A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J. Nucl. Med. 43(11), 1482–1488 (2002)

    PubMed  CAS  Google Scholar 

  41. F. Pacini, E. Molinaro, M.G. Castagna, F. Lippi, C. Ceccarelli, L. Agate, R. Elisei, A. Pinchera, Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 87(9), 4063–4068 (2002)

    Article  PubMed  CAS  Google Scholar 

  42. D. Barbaro, G. Boni, G. Meucci, G. Simi, P. Lapi, P. Orsini, C. Pasquini, F. Piazza, M. Caciagli, G. Mariani, Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J. Clin. Endocrinol. Metab. 88(9), 4110–4115 (2003)

    Article  PubMed  CAS  Google Scholar 

  43. F. Pacini, P.W. Ladenson, M. Schlumberger et al., Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926–932 (2006)

    Article  PubMed  CAS  Google Scholar 

  44. D. Van Nostrand, G.R. Khorjekar, J. O’Neil, S. Moreau, F.B. Atkins, P. Kharazi et al., Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131-I planar whole-body imaging and 124-I PET. J. Nucl. Med. 53, 359–362 (2012)

    Article  PubMed  Google Scholar 

  45. J. Klubo-Gwiezdzinska, K.D. Burman, D. Van Nostrand, M. Mete, J. Jonklaas, L. Wartofsky, Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid 22, 310–317 (2012)

    Article  PubMed  CAS  Google Scholar 

  46. H. Tala, R. Robbins, J.A. Fagin, S.M. Larson, R.M. Tuttle, Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J. Clin. Endocrinol. Metab. 96, 2105–2111 (2011)

    Article  PubMed  CAS  Google Scholar 

  47. S.J. Bonnema, S. Fast, L. Hedgedusw, Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131-I therapy. Endocrine 40, 344–353 (2011)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Leonard Wartofsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wartofsky, L., Van Nostrand, D. Radioiodine treatment of well-differentiated thyroid cancer. Endocrine 42, 506–513 (2012). https://doi.org/10.1007/s12020-012-9729-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9729-5

Keywords

Navigation